Hakutulokset - Yiyun Tang

  • Näytetään 1 - 11 yhteensä 11 tuloksesta
Tarkenna hakua
  1. 1
    Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large‐scale multinational trials (<scp>PROFILE</scp> 1005 and 1007)

    Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large‐scale multinational trials (<scp>PROFILE</scp> 1005 and 1007) Tekijä Sai‐Hong Ignatius Ou, Yiyun Tang, Anna Polli, Keith D. Wilner, Patrick Schnell

    Julkaistu 2016
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK

    Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK Tekijä Ugo De Giorgi, Stephen J. Freedland, Antti Rannikko, M. Backhaus, Arnauld Villers, Jamal Tarazi, Yiyun Tang, Gabriel P. Haas, Matt Rosales, Neal D. Shore

    Julkaistu 2025
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study

    Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study Tekijä Pasi A. Jänne, Alice T. Shaw, D. Ross Camidge, Giuseppe Giaccone, S. Martin Shreeve, Yiyun Tang, Zelanna Goldberg, Jean‐François Martini, Huiping Xu, Leonard P. James, Benjamin Solomon

    Julkaistu 2016
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

    Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC Tekijä S.-H.I. Ou, Pasi A. Jänne, Cynthia Huang Bartlett, Yiyun Tang, D.-W. Kim, Gregory A. Otterson, Lucio Crinò, Paulina Selaru, D. P. Cohen, Jeffrey W. Clark, Gregory J. Riely

    Julkaistu 2014
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    Complex renal cysts associated with crizotinib treatment

    Complex renal cysts associated with crizotinib treatment Tekijä Patrick Schnell, Cynthia Huang Bartlett, Benjamin Solomon, Vanessa Tassell, Alice T. Shaw, Tommaso De Pas, S.D. Lee, Geon Kook Lee, Kaoru Tanaka, Weiwei Tan, Yiyun Tang, Keith D. Wilner, Allan Z. Safferman, Ji‐Youn Han

    Julkaistu 2015
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer

    Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer Tekijä Yi‐Long Wu, Shun Lü, You Lü, Jianying Zhou, Yuankai Shi, Virote Sriuranpong, Jcm Ho, Byoung Chul Cho, Chun‐Ming Tsai, Chin‐Hee Chung, Keith D. Wilner, Yiyun Tang, Elizabeth T. Masters, Paulina Selaru, Tony Mok

    Julkaistu 2018
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

    Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating... Tekijä Tony Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Alka Chawla, Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Kay Noonan, Yiyun Tang, M. Pastel, Keith D. Wilner, Yi‐Long Wu

    Julkaistu 2020
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  8. 8
    Crizotinib in Patients With MET-Amplified NSCLC

    Crizotinib in Patients With MET-Amplified NSCLC Tekijä D. Ross Camidge, Gregory A. Otterson, Jeffrey W. Clark, Sai‐Hong Ignatius Ou, Jared Weiss, Steven Ades, Geoffrey I. Shapiro, Mark A. Socinski, Danielle Murphy, Umberto Conte, Yiyun Tang, Sherry Wang, Keith D. Wilner, Liza C. Villaruz

    Julkaistu 2021
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  9. 9
    1778P Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK

    1778P Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK Tekijä Stephen J. Freedland, Martin Gleave, U.F.F. De Giorgi, Antti Rannikko, Christopher Pieczonka, Swetha Sridharan, Klaus Brasso, Henry H. Woo, Antonio Gómez‐Caamaño, Jeffery W. Saranchuk, L.T. Nordquist, Ubirajara Ferreira, Yiyun Tang, Brad Rosbrook, Gabriel P. Haas, M. Rosales, F. Zohren, Neal D. Shore

    Julkaistu 2023
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  10. 10
    Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

    Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Tekijä Alice T. Shaw, Beow Y. Yeap, Benjamin Solomon, Gregory J. Riely, Justin F. Gainor, Jeffrey A. Engelman, Geoffrey I. Shapiro, Daniel B. Costa, Sai‐Hong Ignatius Ou, Mohit Butaney, Ravi Salgia, Robert G. Maki, Marileila Varella‐Garcia, Robert C. Doebele, Yung‐Jue Bang, Kimary Kulig, Paulina Selaru, Yiyun Tang, Keith D. Wilner, Eunice L. Kwak, Jeffrey W. Clark, A. John Iafrate, D. Ross Camidge

    Julkaistu 2011
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  11. 11
    Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

    Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Tekijä D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak, A. John Iafrate, Marileila Varella‐Garcia, Stephen B. Fox, Gregory J. Riely, Benjamin Solomon, Sai‐Hong Ignatius Ou, Dong‐Wan Kim, Ravi Salgia, P. Fidias, Jeffrey A. Engelman, Leena Gandhi, Pasi A. Jänne, Daniel B. Costa, Geoffrey I. Shapiro, Patricia LoRusso, Katherine Ruffner, Patricia Stephenson, Yiyun Tang, Keith D. Wilner, Jeffrey W. Clark, Alice T. Shaw

    Julkaistu 2012
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: